These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31129014)

  • 1. The effect of a GnRH antagonist on follicle maturation in normal women.
    Pousias S; Messini CI; Anifandis G; Sveronis G; Georgoulias P; Daponte A; Messinis IE; Dafopoulos K
    Reprod Biomed Online; 2019 Jul; 39(1):84-92. PubMed ID: 31129014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
    European and Middle East Orgalutran Study Group
    Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).
    Nelson LR; Fujimoto VY; Jaffe RB; Monroe SE
    Fertil Steril; 1995 May; 63(5):963-9. PubMed ID: 7536693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
    Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge.
    Fraser HM; Lunn SF; Morris KD; Deghenghi R
    Hum Reprod; 1997 Mar; 12(3):430-5. PubMed ID: 9130734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a GnRH antagonist in conjunction with low amplitude, high frequency LH pulses to induce follicular growth without an LH surge and ovulation in ewes.
    Dobson H; Campbell BK; Scaramuzzi RJ
    Anim Reprod Sci; 1997 Apr; 46(3-4):213-22. PubMed ID: 9231261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
    Hohmann FP; Laven JS; Mulders AG; Oberyé JJ; Mannaerts BM; de Jong FH; Fauser BC
    J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial.
    Lambalk CB; Leader A; Olivennes F; Fluker MR; Andersen AN; Ingerslev J; Khalaf Y; Avril C; Belaisch-Allart J; Roulier R; Mannaerts B
    Hum Reprod; 2006 Mar; 21(3):632-9. PubMed ID: 16361296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuating activity of the ovary on LH response to GnRH during the follicular phase of the cycle.
    Dimitraki M; Messini CI; Dafopoulos K; Gioka T; Koutlaki N; Garas A; Georgoulias P; Messinis IE
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):439-43. PubMed ID: 23909480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
    Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
    J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the role of LH in the maturation of the pre-ovulatory follicle in a sheep using a GnRH-antagonist.
    Campbell BK; Dobson H; Baird DT; Scaramuzzi RJ
    Anim Reprod Sci; 1997 Aug; 48(2-4):219-34. PubMed ID: 9452875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST; Thong KJ; Baird DT
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462).
    Itskovitz-Eldor J; Kol S; Mannaerts B; Coelingh Bennink H
    Hum Reprod; 1998 Feb; 13(2):294-5. PubMed ID: 9557825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.